重组人脑利钠肽对急性心肌梗死患者经皮冠状动脉介入术后脑钠肽水平及心功能的影响

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Recombinant Human Brain Natriuretic Peptide in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Methods A total of 84 AMI patients admitted to Tengzhou Hospital of Traditional Chinese Medicine from July 2018 to December 2020 were selected and divided into control group and observation group by random number table method, with 42 cases in each group. The control group was given conventional drug therapy after PCI, and the observation group was treated with Recombinant Human Brain Natriuretic Peptide, both groups were followed up for 6 months after treatment. Clinical efficacy, cardiac function,brain natriuretic peptide (BNP) level and incidence of adverse events were compared between the two groups. Results The total effective rate of clinical treatment and left ventricular ejection fraction (LVEF) in the observation group were higher than those in the control group, BNP level, total incidence of adverse events were lower than those in the control group, left ventricular diastolic diameter (LVEDD) and left ventricular posterior wall thickness (LVPWT) were less than those in the control group, the differences were statistically significant (P＜0.05). Conclusion The application of Recombinant Human Brain Natriuretic Peptide in AMI patients after PCI can improve the cardiac function, reduce the level of BNP and the incidence of adverse events, which is conducive to the prognosis of patients.

Key words： Acute myocardial infarction Percutaneous coronary intervention Recombinant Human Brain Natriuretic Peptide Brain natriuretic peptide Cardiac function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XING Dong
	LIAO Peichao
	MA Zhiqiang

Cite this article:

XING Dong,LIAO Peichao,MA Zhiqiang. Effects of Recombinant Human Brain Natriuretic Peptide on brain natriuretic peptide level and cardiac function in patients with acute myocardial infarction after percutaneous coronary intervention[J]. 中国当代医药, 2022, 29(16): 100-102.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I16/100

[1]	鲜文.重组人BNP 联合黄芪注射液对AMI PCI 术后心力衰竭患者心功能及血清炎症因子的影响[J].心血管康复医学杂志，2019，28（4）：424-428.
[2]	及孟，李光智，余洪，等.破格救心汤联合重组人脑利钠肽对急性心力衰竭患者心功能及血清BNP，CK-MB 和cTnI 水平的影响[J].中国中医急症，2019，28（9）：1524-1527.
[3]	胡法国，张莹，马翔宇.经皮冠状动脉介入治疗对老年急性心肌梗死患者心血管事件的影响及相关因素研究[J].中国临床医生杂志，2020，48（2）：167-170.
[4]	中华医学会心血管病学分会，中华心血管病杂志编辑委员会.急性ST 段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志，2015，43（5）：380-393.
[5]	张强，刘珂，牛红梅，等.早期应用重组人脑利钠肽对前壁AMI 急诊PCI 术后心肌存活性及心功能的影响[J].中国心血管病研究，2018，16（5）：407-411.
[6]	田丽晓，秦历杰，王龙安，等.糖化血红蛋白联合脑钠肽对老年急性心肌梗死住院患者临床预后的评估价值[J].中华老年医学杂志，2020，39（10）：1174-1177.
[7]	冷博，吕飞，胡娟.重组人脑利钠肽对老年急性心肌梗死急诊介入术患者心功能的影响[J].西部医学，2018，30（7）：1019-1022.
[8]	刘虹宏，刘兆川，张誉籍，等.替格瑞洛联合重组人脑利钠肽对急性心肌梗死患者经皮冠状动脉介入术后微循环改善及心肌损伤标志物的影响[J].中国医药，2019，14（3）：330-334.
[9]	徐国旺.冠状动脉介入治疗冠心病急性心肌梗死的临床疗效及其对心室重构的影响[J].中国医药科学，2021，11（1）：225-228.
[10]	焦祺.急诊经皮冠状动脉介入治疗急性心肌梗死患者的效果[J].中国当代医药，2022，29（4）：89-92.
[11]	何战斌，陈圆圆，樊旺祥，等.重组人脑利钠肽对老年急性心肌梗死患者经皮冠状动脉介入治疗后心功能及组织灌注的影响[J].安徽医学，2018，39（8）：955-959.
[12]	孟利民，杨华，常超，等.重组人脑钠肽对急性心肌梗死患者急诊介入后血清趋化素和白细胞介素37 的影响[J].中华老年心脑血管病杂志，2018，20（4）：378-381.
[13]	汪兵，庹田.重组人脑利钠肽在急性心肌梗死PCI 后患者心肾功能的保护作用[J].药物生物技术，2019，26（2）：136-139.
[14]	魏显敬，谢莲娜，王凯君，等.重组人脑利钠肽对急性失代偿性心力衰竭患者血流动力学及心功能的影响[J].海南医学，2018，29（4）：452-455.
[15]	张大程，张春雨，鹿梦溪.重组人脑利钠肽联合参附注射液对急性心肌梗死合并泵衰竭患者心功能及神经内分泌激素水平的影响[J].河北医药，2018，40（1）：19-22.
[16]	陈骅，刘昕.重组人脑利钠肽对急性前壁心梗急诊经皮冠状动脉介入术后心室重塑和心功能的影响[J].中国医药导报，2018，15（2）：58-61.
[17]	扈晓霞，韩世飞，李秋梅，等.重组人脑利钠肽联合厄贝沙坦对心肌梗死PCI 术后患者疗效及HCY，IMA，Lp-PLA2影响[J].中国现代应用药学，2019，36（22）：2848-2852.